Acute Cytokine Response During Breast Cancer Surgery: Potential Role of Dexamethasone and Lidocaine and Relationship with Postoperative Pain and Complications – Analysis of Three Pooled Pilot Randomized Controlled Trials

Sandra AS van den Heuvel, 1 Selina El van der Wal, 1 Ewald M Bronkhorst, 1 Michiel C Warlé, 1 May Ronday, 1 Judith Plat, 1 Nens van Alfen, 2 Leo AB Joosten, 3 Jos GC Lerou, 4 Kris CP Vissers, 1 Monique AH Steegers 1

1Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands; 2Department of Health Evidence, Radboud University Medical Centre, Nijmegen, the Netherlands; 3Division of Vascular and Transplant Surgery, Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands; 4Department of Anesthesiology, Alexander-Monroe Breast Cancer Hospital, Biltoven, the Netherlands; 5Donders Institute for Brain Cognition and Behavior; Department of Neurology, Radboud University Medical Centre, Nijmegen, the Netherlands; 6Department of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud University Medical Centre, Nijmegen, the Netherlands; 7Department of Anesthesiology, Pain and Palliative Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands

Correspondence: Sandra AS van den Heuvel
Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Nijmegen Medical Center, Internal mail 630, P.O. Box 9101, Nijmegen 6525 GA, the Netherlands
Tel +31 243615244
Email Sandra.vandenHeuvel@radboudumc.nl

Purpose: An imbalance in perioperative cytokine response may cause acute pain and postoperative complications. Anesthetic drugs modulate this cytokine response, but their role in non-major breast cancer surgery is unclear. In an exploratory study, we investigated whether intravenous lidocaine and dexamethasone could modulate the cytokine response into an anti-inflammatory direction. We also evaluated interrelationships between cytokine levels, pain scores and postoperative complications. Our goal is to develop multimodal analgesia regimens optimizing outcome after breast cancer surgery.

Patients and Methods: Forty-eight patients undergoing a lumpectomy were randomly assigned to placebo or lidocaine (1.5 mg.kg⁻¹ followed by 2 mg.kg⁻¹.hour⁻¹) supplemented by dexamethasone zero, 4 or 8 mg, yielding six groups of eight patients. Interleukin (IL)-1β, IL-1Ra, IL-6, IL-10 levels and pain scores were measured at baseline and four hours postoperatively. We assessed postoperative complications occurring within 30 days. We noted persistent pain and infections as potential immune-related complications (PIRC). We used multiple regression to disentangle the effects of the individual study drugs (given by their partial regression coefficients (b)). Odds ratios (OR) estimated the link between pain scores and complications.

Results: Dexamethasone 8 mg increased IL-10 (b=12.70 (95% CI=8.06–17.34), P<0.001). Dexamethasone 4 mg and 8 mg decreased the ratio IL-6/IL-10 (b=−2.60 (−3.93 to −1.26), P<0.001 and b=−3.59 (−5.04 to −2.13), P<0.001, respectively). We could not show modulatory effects of lidocaine on cytokines. High pain scores were linked to the occurrence of PIRC’s (OR=2.028 (1.134–3.628), P=0.017). Cytokine levels were not related either to acute pain or PIRC.

Conclusion: Dexamethasone modulated the perioperative cytokine response into an anti-inflammatory direction. An overall lidocaine effect was not found. Patients with higher pain scores suffered from more 30-day PIRCs. Cytokine levels were not associated with pain or more postoperative complications, even not with PIRC. Larger studies in breast cancer surgery are needed to confirm these explorative results.

Keywords: acute pain, anesthetic agents, immune response, lumpectomy, perioperative outcomes

Plain Language Summary
Cytokines are small proteins that are crucial in controlling the activity of the body’s immune system. The body’s response to an injury or other trigger like surgery is called “inflammation”.

This article was published in the following Dove Press journal: Journal of Pain Research
Surgery is a cornerstone of breast cancer treatment, but induces the release of pro-inflammatory and anti-inflammatory cytokines. An imbalance in the pro-inflammatory direction results in more pain and more morbidity after an operation. This may contribute to the potential negative impact of breast cancer surgery on the quality of life in up to half of the patients. Anesthetic drugs used during surgery, such as lidocaine and dexamethasone, may however counteract the cytokine imbalance beneficially.

What Is Unknown?

- The impact of dexamethasone and lidocaine on cytokine responses is unclear for patients undergoing conservative breast cancer surgery, like lumpectomy without axillary lymph node dissection.
- The interrelationships between cytokine levels, pain scores and complications after lumpectomy are unknown.

We investigated 48 patients undergoing breast cancer surgery to answer two questions. Do lidocaine and/or dexamethasone steer the immune response into a beneficial anti-inflammatory direction? Does an interrelationship exist between cytokine levels, pain scores and postoperative complications?

What This Article Adds

- The immune response of patients receiving dexamethasone 4 mg or 8 mg goes into an anti-inflammatory direction.
- Patients experiencing less pain suffer less from postoperative complications.

Results for lidocaine were inconclusive and we could not demonstrate a link between patient’s cytokine levels and complications. Larger studies are thus needed to confirm our results and to help optimizing perioperative outcomes.

**Introduction**

Surgery is a cornerstone of breast cancer treatment, but induces a systemic inflammatory response characterized by the release of cytokines. Proinflammatory cytokines like interleukin (IL)-1β, IL-6 and tumor necrosis factor alpha are released after tissue injury. Anti-inflammatory cytokines, like IL-10 and IL-1Ra, are also released to restore homeostasis. An imbalance between pro- and anti-inflammatory cytokines activates an inflammatory cascade resulting in increased postsurgical morbidity. Increased levels of IL-6 and ratio of IL-6/IL-10 are proven predictors for developing infectious complications after surgery.

Postoperative pain, chronic pain and postoperative infectious complications contribute to the overall negative impact of breast cancer surgery on the quality of life in up to half of the patients. Acute postoperative pain, which is a predictive factor for the development of chronic pain, may be related to the inflammatory responses after surgery. This may help to explain why higher pain scores after surgery contribute to postoperative complications, especially health care-associated infections.

Various pharmacological regimens proved to counteract the surgery-induced proinflammatory response beneficially, thus reducing morbidity after operation. Dexamethasone, given in a high dose of up to 100 mg before cardiac surgery with cardiopulmonary bypass, shifted the cytokine profile into the anti-inflammatory direction. Intravenous (IV) lidocaine attenuates the hyperinflammatory response after tissue injury, thus reducing pain and improving outcomes.

For patients undergoing breast cancer surgery, and specifically in conservative surgery like lumpectomy without axillary lymph node dissection, the impact of dexamethasone and IV lidocaine on cytokine responses is unclear. The question thereby arises if a single low dose of dexamethasone could be effective enough. Four mg is commonly administered for its anti-emetic effect and 8 mg for its additional analgesic effect. Furthermore, the interrelationships between cytokine levels, pain scores and postoperative complications after lumpectomy have not yet been investigated. Understanding immune-mediated mechanisms underlying acute pain and complications could help develop multimodal analgesia regimens and optimize outcome after breast cancer surgery.

Therefore, we performed an explorative study including patients undergoing a lumpectomy for breast cancer. First, we aimed to evaluate whether a low dose of dexamethasone or IV lidocaine modulates the early cytokine response into an anti-inflammatory direction. Second, we aimed to confirm the link between higher pain scores and 30-day surgical complications. Third, we aimed to investigate whether a proinflammatory-oriented cytokine balance is associated with higher pain scores and immune-mediated surgical complications.

**Patients and Methods**

We consecutively performed three double blinded randomized controlled trials at the Alexander Monro Hospital, a non-teaching hospital (10 hospital beds) specialized in breast cancer care (Bilthoven, The Netherlands). The Institutional Review Board approved all study protocols and documents. The study was registered prior to patient enrollment at the European Clinical Trial Register (EudraCT 2012–002222-70; Principal Investigator: Prof. K.C.P. Vissers; Date of registration: November 15, 2013). The protocol can be accessed after a reasonable request at protocols.io
Patients
We assessed potential participants for eligibility during the preoperative anesthesia consultation. Female patients aged older than 18 years undergoing primary breast cancer surgery without axillary lymph node dissection were eligible for inclusion. Exclusion criteria were: allergy to amide type local anesthetics, myocardial ischemia within the previous six months, hypokalemia (<3.5 mmol·L⁻¹), renal impairment (creatinine clearance < 60 mL·min⁻¹·1.73m⁻²) or liver function impairment (international normalized ratio > 1.8), pregnancy or breastfeeding, use of anti-arrhythmic drugs, chronic opioid use, a history of chronic pain, corticosteroid use, and the inability to provide written informed consent.

Patient Groups
In the three consecutive studies, patients received no dexamethasone or dexamethasone 4 mg or dexamethasone 8 mg before induction of general anesthesia. In each of the studies, patients were randomly assigned in a 1:1 ratio to one of two groups (IV lidocaine or IV placebo) using a sealed envelope with blocks of eight.

An external pharmacy delivered the blinded study medication to the anesthetic department in identically appearing 50 mL syringes. Lidocaine 1.5 mg·kg⁻¹ or placebo (saline 0.9% in the same volume) was administered as a bolus in ten minutes before induction of anesthesia, followed by a continuous infusion of IV lidocaine at 2 mg·kg⁻¹·hour⁻¹ or placebo until one hour after end of surgery. The lidocaine dosing regimen is consistent with most references, but the optimal dosing is unknown. Potential adverse events caused by IV lidocaine were noted. They were reported by patients or observed by site staff monitoring patient’s vital signs.

Measurements
There were four measuring points: at baseline, when patients arrived on the operation theater complex before surgery (t0), admission on post-anesthesia care unit (PACU) (t1), 4 hours after end of surgery (t2), and 30 days after surgery.

Pain scores were assessed using the Numeric Rating Scale (NRS 0 = no pain, NRS 10 = worst pain imaginable). NRS was recorded at t0, t1, and t2.

Cytokine levels of IL-6, IL-10, IL-1β and IL-1Ra were measured at t0 and t2. Ethylenediaminetetraacetic anticoagulated blood was centrifugated immediately after withdrawal at 2000 x g for ten minutes at 4°C, after which plasma was stored at −80°C. Cytokines were analyzed batch-wise by Simplex Assays™ according to the manufacturer’s instructions as previously described. Baseline levels of low abundance cytokines, including IL-6, IL-10 and IL-1β, proved to be below the lower limit of quantification by standard enzyme-linked immunosorbent assays. The Ella microfluidic analyzer (Protein Simple, San Jose, CA, USA) was therefore used to assess cytokine concentrations in the fg·mL⁻¹ to low pg·mL⁻¹ range.

We classified any medical adverse outcome occurring between admission and 30 days after surgery according to the Clavien Dindo Classification (CDC) of surgical complications. The CDC systematically scores postoperative complications in five grades and is a preferred method for outcome assessment after surgery. A complication with a potential immune-mediated pathway, i.e., an infection or persistent postsurgical pain, was noted as a potential immune-related complication (PIRC). The study physician searched retrospectively for complications and then classified them according to CDC. A medical researcher, who was not involved in the study or patient’s care, checked the records to ensure completeness of data.

Perioperative Management
Acetaminophen 1 gr PO was given one hour before operation. We induced anesthesia with IV propofol and sufentanil and maintained it with continuous infusion of IV propofol supplemented with sufentanil according to clinical needs. The total dose of sufentanil at end of surgery was recorded. Intraoperative monitoring included pulse oximetry, capnography, electrocardiography and non-invasive blood pressure measurement. IV diclofenac 75 mg was administered at the end of surgery unless there was a contraindication for non-steroidal anti-inflammatory drugs.

Patients remained at the PACU for at least one hour until discontinuation of the study medication. Nurses assessed postoperative nausea and vomiting and the Aldrete score per standard protocols. Patients with NRS ≥ 4 at admission on the PACU received IV piritramide 2.5 mg at ten minutes intervals until NRS ≤ 3. Clonidine 75 μg
was given at ten minutes intervals when, despite administra-
tion of piritramide, the NRS remained ≥4 on condition
that the heart rate was ≥80 bpm and systolic blood pressure
was ≥120 mmHg. Postoperative pain management on
the ward consisted of acetaminophen 1 gram four times
daily, diclofenac 50 mg three times daily and piritramide
0.1 mg·kg⁻¹ six times daily as needed.

After discharge patients received standard care. One
week post-surgery a follow-up visit was scheduled with a
nurse and the surgeon. Thereafter, patients received regu-
lar clinical care by their radiotherapist, surgeon or nurse,
depending on their oncologic plan. Postoperative compli-
cations were documented in patients’ records.

Statistical Analysis
Our study is based upon the analysis of pooled data
obtained in three consecutive randomized controlled trials.
As this was an exploratory study, no formal sample size
calculation was made. Our results should, therefore, be
regarded as explorative and hypothesis-generating.

Results for all variables are given as mean (SD) [mini-
umum–maximum], unless stated otherwise. The differences
between plasma levels of cytokines at t2 and those at t0
are given as ΔIL-6, ΔIL-10, ΔIL-1β and ΔIL-1Ra. The
balance between pro- and anti-inflammatory cytokines is
described by the ratio of IL-6/IL-10 and the ratio of IL-1β/
IL-1Ra. The differences between these ratios at t2 and
those at t0 are given as ΔIL-6/IL-10 and ΔIL-1β/IL-1Ra.

Multiple linear regression analysis was used to evalu-
ate the null hypothesis that lidocaine or dexamethasone
had no effect on ΔIL-6, ΔIL-10, ΔIL-1β, ΔIL-1Ra, ΔIL-6/
ΔIL-10 and ΔIL-1β/ΔIL-1Ra. Descriptive analysis preceded
formal statistical analysis. Based on a striking pattern in
the dataset, we introduced “post hoc” the duration of
surgery as an independent variable.

Univariate binary logistic regression models using
pooled data were estimated to evaluate the potential asso-
ciation between NRS at t2 and the occurrence of any
complication according to CDC or a PIRC. The associa-
tion between the cytokine levels and their ratios at t0 and
t2 on one hand, and the occurrence of a PIRC on the other
hand, was evaluated similarly.

A Spearman’s Rho correlation was used to determine if
NRS at t2 was related to each of the cytokine levels at t0
and t2.

Statistical analysis was performed using IBM SPSS
Statistics V25.0 and GraphPad Prism V8.0 (GraphPad
Software). P<0.05 was considered statistically significant.

Results
We analyzed data for 48 patients with eight patients in
each of six groups (Figure 1).

The six groups were similar in respect of physical and
clinical characteristics, except surgery duration (Table 1).
All patients underwent breast-conserving surgery with a sentinel
node biopsy. The intraoperative and direct postoperative
course was uneventful. All patients could be discharged
from the PACU one hour after admission (Aldrete score ≥13).

We supply patients’ characteristics of pooled lidocaine
groups and pooled dexamethasone groups in the
Supplementary Table S1 and all raw cytokine levels in the
Supplementary Table S2. IL-1β levels at baseline
were lower in the study with dexamethasone 8 mg than
those in the other two studies.

Pain and Its Treatment
Pain scores and pain treatment are summarized in Table 1.
At t1, 94% of the patients had NRS ≤ 4 and 96% at t2.
Opioid and diclofenac use was similar among patient
groups during and after operation. Rescue drug clonidine
was not administered in the third trial where dexametha-
sone 8 mg was given alone or combined with IV lidocaine.

Postoperative Complications
A total of 23 postoperative complications occurred in 22
(45.8%) patients (Table 1). Sixteen patients (33% of the
total) had a CDC grade I complication. Four patients (8%)
had a CDC grade II, and two patients had a CDC grade III
complication. The groups were similar in respect of
complications.

Eight patients suffered from a PIRC: persistent pain
(n=3), mucositis (1), surgical site infection treated with
antibiotics (2), and abscess treated with antibiotics and
surgery (2). Fourteen patients suffered from the following
complications: hematoma (6), seroma (3), nausea (3), con-
stipation (1), light headedness (1), and a transient ischemic
attack (1). One of these fourteen patients suffered from
two CDC grade I complications.

Effects of Dexamethasone and Lidocaine
on Postoperative Cytokine Levels
Figures 2 and 3 reveal patterns in the individual observa-
tions. Observations above the zero line in Figures 2 and 3
are increases in cytokine levels or their ratios between t0
and t2.
In most patient groups the levels of IL-6 and IL-10 (Figure 2A and B) and IL-1Ra (Figure 3B) seemed to increase after surgery. In contrast, IL-1β levels (Figure 3A) appeared not to change. Lidocaine had little or no effect on the cytokine levels and their ratios in comparison with placebo (Figures 2A and C, 3A–C), except that it seemed to increase IL-10 levels when combined with dexamethasone 8 mg (Figure 2B). Dexamethasone 4 and 8 mg appeared to reverse ΔIL-6/IL-10 (Figure 2C) but seemed to have no effect on IL-6 (Figure 2A), IL-1β (Figure 3A), and IL-1Ra (Figure 3B) levels. Dexamethasone 8 mg appeared to increase the IL-10 level (Figure 2B). Figures 2C and 3C suggest that a longer duration of surgery increased ΔIL-6/IL-10 but decreased ΔIL-1β/IL-1Ra.

Multiple regression confirms our descriptive analysis and untangles the separate effects of lidocaine, dexamethasone 4 mg, dexamethasone 8 mg and duration of surgery (Table 2). An overall effect of lidocaine on measured cytokines was not found. There is only suggestive evidence that dexamethasone 4 mg increased IL-10 level (P=0.045; positive “b” in Table 2 means increase). Dexamethasone 4 mg decreased IL-6/IL-10 (P<0.001; negative “b” means decrease). Dexamethasone 8 mg increased the IL-10 level (P=0.001) and decreased IL-6/IL-10 (P<0.001). As a “post hoc” independent variable the duration of surgery increased postoperative IL-6 levels (P=0.026) and IL-6/IL-10 (P=0.04), but decreased IL-1β/IL-1Ra (P=0.016).
increase in IL-6 level was 0.162 pg·mL⁻¹ per minute or 9.72 pg·mL⁻¹ per hour of surgery time, independently from the other independent variables.

IL-1Ra increased from 268 pg·mL⁻¹ to 8075 pg·mL⁻¹ in one patient of the dexamethasone 8 mg-lidocaine group (Figure 3B). As this outlier was not an influential observation, it was not excluded from regression analysis.

### Relationships Between Cytokine Levels, Pain Scores and Postoperative Complications

Patients who experienced higher pain scores at t2 seemed to be prone to suffer from any complication according to CDC within 30 days after surgery (OR=1.464, 95% CI=0.941–2.278; P=0.091) (Table 3). A statistically significant association exists between having postoperative

### Table 1 Patients’ Perioperative Characteristics in the Three Consecutive Randomized Controlled Trials

<table>
<thead>
<tr>
<th></th>
<th>RCT 1: No Dexamethasone</th>
<th>RCT 2: Dexamethasone 4 mg</th>
<th>RCT 3: Dexamethasone 8 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo, n=8</td>
<td>Lidocaine, n=8</td>
<td>Placebo, n=8</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>55 (13) [34–73]</td>
<td>59 (11) [42–75]</td>
<td>61 (12) [43–75]</td>
</tr>
<tr>
<td></td>
<td>26 (5) [20–34]</td>
<td>28 (6) [20–36]</td>
<td>25 (5) [20–33]</td>
</tr>
<tr>
<td>BMI (kg m⁻²)</td>
<td>26 (5) [20–34]</td>
<td>26 (6) [20–36]</td>
<td>25 (5) [20–33]</td>
</tr>
<tr>
<td>ASA physical status (n)</td>
<td>2</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>T = 1</td>
<td>6</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>T = 2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Tumour classification (n)</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Carcinoma in situ</td>
<td>4</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>T1</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>T2</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Node classification (n)</td>
<td>7</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>N0</td>
<td>7</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>N1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>N2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery duration (min)</td>
<td>109 (42) [39–152]</td>
<td>87 (35) [35–156]</td>
<td>76 (18) [58–110]</td>
</tr>
<tr>
<td>Sufentanil (µg kg⁻¹ hr⁻¹)</td>
<td>0.32 (0.09) [0.20–0.45]</td>
<td>0.25 (0.13) [0.13–0.54]</td>
<td>0.29 (0.09) [0.17–0.43]</td>
</tr>
<tr>
<td>NRS At t0</td>
<td>0.9 (1.1) [0–3]</td>
<td>0.1 (0.4) [0–1]</td>
<td>0.3 (0.5) [0–1]</td>
</tr>
<tr>
<td>At t1</td>
<td>1.6 (2.1) [0–5]</td>
<td>1.5 (1.5) [0–4]</td>
<td>1.3 (1.8) [0–5]</td>
</tr>
<tr>
<td>At t2</td>
<td>2.4 (1.2) [0–7]</td>
<td>1.8 (1.5) [0–4]</td>
<td>1.9 (1.1) [0–4]</td>
</tr>
<tr>
<td>Diclofenac (mg)</td>
<td>0 mg</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>75 mg</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>125 mg</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Piritramide (mg)</td>
<td>9.7 (6.0) [0–20]</td>
<td>8.1 (5.8) [0–20]</td>
<td>8.8 (4.8) [5–20]</td>
</tr>
<tr>
<td>Clonidine (µg)</td>
<td>0 µg</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>75 µg</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>150 µg</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>30-Day complications (N)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDC I</td>
<td>2</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>CDC II</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CDC IIIb</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Notes: Data are mean (SD) [minimum–maximum], number of patients (n) or number of complications (N). At t0 = baseline, t1 = direct postoperative, and t2 = 4 hours after surgery.

Abbreviations: RCT, randomized controlled trial; BMI, body mass index; ASA, American Society of Anesthesiologists; T, tumor staging; NRS, Numeric Rating Scale; CDC, Clavien Dindo Classification.
Figure 2 Difference ($\Delta$) between interleukin (IL)-6, IL-10 plasma levels and ratio IL-6/IL-10 at baseline ($t_0$) and those 4 hours after surgery ($t_2$) in six groups (n=8 per group). Each symbol represents one patient. A symbol above or below the zero line represents an increase or decrease, respectively, from $t_0$ to $t_2$. Error bars are the 25th–75th percentiles around the medians. (A) Observations for $\Delta$IL-6 and (B) for $\Delta$IL-10 per group. (C) Observations for the ratio $\Delta$IL-6/IL-10 per group and linear regression of the pooled observations on the duration of surgery. The full regression line is accompanied with dotted lines showing its 95% confidence limits. There is one missing value in the group dexamethasone 8 mg with placebo for $\Delta$IL-10 and $\Delta$IL-6/IL-10. Plac, placebo; Dexa, dexamethasone; Lido, lidocaine.
Figure 3 Difference (Δ) between interleukin (IL)-1β, IL-1Ra plasma levels and ratio IL-1β/IL-1Ra at baseline (t0) and those 4 hours after surgery (t2) in six groups (n=8 per group). Each symbol represents one patient. A symbol above or below the zero line represents an increase or decrease, respectively, from t0 to t2. Error bars are the 25th–75th percentiles around the medians. (A) Observations for ΔIL-1β and (B) for ΔIL-1Ra per group. (C) Observations for the ratio ΔIL-1β/IL-1Ra per group and linear regression of the pooled observations on the duration of surgery. The full regression line is accompanied with dotted lines showing its 95% confidence limits. Plac, placebo; Dexa, dexamethasone; Lido, lidocaine.
Table 2 The Effects (Column “b”) of Lidocaine, Dexamethasone 4 mg, Dexamethasone 8 mg and Surgery Duration on the Levels of Interleukins and Their Ratios After Surgery

<table>
<thead>
<tr>
<th></th>
<th>IL-6 (95% CI)</th>
<th>P</th>
<th>IL-10 (95% CI)</th>
<th>P</th>
<th>IL-6/IL-10 (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>b</strong></td>
<td></td>
<td></td>
<td><strong>b</strong></td>
<td></td>
<td><strong>b</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Intercept</strong></td>
<td>2.03 (0.820)</td>
<td>0.005</td>
<td>2.61 (0.160)</td>
<td>0.137</td>
<td>0.160</td>
<td>0.057</td>
</tr>
<tr>
<td><strong>Lidocaine</strong></td>
<td>3.02 (0.468)</td>
<td>0.121</td>
<td>4.37 (0.137)</td>
<td>0.045</td>
<td>0.012</td>
<td>0.824</td>
</tr>
<tr>
<td><strong>Dexamethasone 4 mg</strong></td>
<td>-3.54 (0.494)</td>
<td>0.701</td>
<td>(0.018-8.65)</td>
<td>0.121</td>
<td>-2.60</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Dexamethasone 8 mg</strong></td>
<td>-8.04 (0.152)</td>
<td>0.121</td>
<td>(8.06-17.34)</td>
<td>&lt;0.001</td>
<td>-3.59</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Surgery time (min)</strong></td>
<td>0.162 (0.026)</td>
<td>0.536</td>
<td>(0.005-0.111)</td>
<td>0.074</td>
<td>0.019</td>
<td>0.040</td>
</tr>
<tr>
<td></td>
<td>R² = 0.227</td>
<td></td>
<td>R² = 0.449</td>
<td></td>
<td>R² = 0.526</td>
<td></td>
</tr>
<tr>
<td><strong>ΔIL-1β</strong></td>
<td>0.83 (0.043)</td>
<td>0.699</td>
<td>124 (0.852)</td>
<td>0.960</td>
<td>0.88</td>
<td>0.701</td>
</tr>
<tr>
<td><strong>Lidocaine</strong></td>
<td>-0.08 (0.699)</td>
<td>0.367</td>
<td>(319-1053)</td>
<td>0.287</td>
<td>-0.11</td>
<td>(0.67-0.45)</td>
</tr>
<tr>
<td><strong>Dexamethasone 4 mg</strong></td>
<td>-0.49 (0.062)</td>
<td>0.737</td>
<td>(1193-517)</td>
<td>0.430</td>
<td>-0.07</td>
<td>(0.76-0.63)</td>
</tr>
<tr>
<td><strong>Dexamethasone 8 mg</strong></td>
<td>-0.39 (0.167)</td>
<td>0.559</td>
<td>(69-1189)</td>
<td>0.559</td>
<td>-0.21</td>
<td>(0.96-0.53)</td>
</tr>
<tr>
<td><strong>Surgery time (min)</strong></td>
<td>-0.004 (0.229)</td>
<td>0.942</td>
<td>(1123-1207)</td>
<td>0.942</td>
<td>-0.012</td>
<td>(0.021-0.002)</td>
</tr>
<tr>
<td></td>
<td>R² = 0.097</td>
<td></td>
<td>R² = 0.070</td>
<td></td>
<td>R² = 0.134</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Results are intercept and partial regression coefficients (b) with their 95% CI obtained from multiple regression analysis. *Results for IL-1β/IL-1Ra are to be multiplied by 10⁻³. Δ, difference between the levels of IL and their ratios at baseline and those at 4 hours after surgery. R², coefficient of determination.
Abbreviations: IL, interleukin; CI, confidence interval.

Discussion

This prospective explorative study in 48 patients undergoing a lumpectomy for breast cancer has several findings, but the small sample size in each group precludes drawing firm conclusions. Dexamethasone 4 mg or 8 mg, but not IV lidocaine, modulated the early cytokine response into an anti-inflammatory direction. Raw cytokines levels were not clearly related to postoperative pain scores or the occurrence of a PIRC. However, there was suggestive evidence that a more pro-inflammatory cytokine balance at baseline could result in more PIRC’s.

Despite the small number of patients, we may be more confident in the evidence supporting a link between higher pain scores noted 4 hours postoperatively and PIRC in our homogenous group of patients as our finding accords with previous research. In a cohort of 1014 patients undergoing a broad spectrum of surgeries, higher pain scores or unacceptable pain after surgery were associated with more 30-day complications, especially health care-associated infections.

Anesthetic agents may aid to improve postoperative outcomes by counteracting the neuroendocrine stress response to surgery or through a direct effect on immune cells. The choice of anesthetic agents can even be crucially important for patients with pre-existing immune dysfunction or tumor burden. However, the impact of lidocaine or dexamethasone, which have different immune-modulating effects on cytokine responses, has not been investigated after lumpectomy.

IV lidocaine is known to reduce a hyperinflammatory response, and to decrease proinflammatory cytokines in abdominal surgery. Under the circumstances of our study no overall effect of lidocaine on postoperative
cytokine levels was found. Most likely, lumpectomy is a surgical procedure with less inflammatory stimuli,23 where lidocaine may have little effect.

Dexamethasone’s anti-inflammatory effects depend on its dosage in relation to the extent of tissue trauma. After high dose corticosteroids for major abdominal or thoracic surgery, earlier reports demonstrated a shift towards an anti-inflammatory balance characterized by suppressed IL-6 and increased IL-10 levels, while effects on IL-1 and IL-1Ra levels were absent or showed a decrease.12,25,26 A lower dose, like dexamethasone 8 mg, during abdominal surgery had no effect on IL-10 levels, and reduced27 or showed no effect on IL-6 levels.28 As lumpectomy can be regarded as minimally invasive surgery, when compared with abdominal or cardiac surgery, a less pronounced increase of pro-inflammatory cytokines could be expected. Accordingly, we found a decrease in IL-10 levels and in the ratio IL-6/IL-10, but no significant effect on the levels of IL-6 and IL-1β. Surprisingly, patients in the third pilot study had pre-existent lower levels of IL-1β, which could have masked a potential effect of dexamethasone 8 mg on the postoperative IL-1β levels in this group.

Increased IL-6 levels proved to be related to infectious complications3,4 and higher pain levels.29,30 Also in pathological pain models, elevated expressions of IL-6 and IL-1β in the spinal cord and dorsal root ganglia have been found.31,32 In our study we found a link between higher pain scores and more PIRCs, suggesting a similar underlying immune-mediated mechanism. However, we failed to find a statistically significant relation between cytokine levels and pain scores or PIRCs. Besides a small sample size, potential explanations are: the postoperative cytokine response was influenced by dexamethasone, the postoperative inflammatory response was minimal, the time of measurement was not well chosen, or the range of pain scores was too small. Interestingly, patients with a pre-existent higher IL-6 to IL-10 ratio tended to develop more postoperative complications, which can indicate a vulnerability in a subset of patients.

Our study was not powered to find a statistically significant difference in postoperative pain scores between patient groups, but a clear pattern was present. All patients, who received dexamethasone 8 mg, did not need extra clonidine as rescue analgesic. Those patients who received also lidocaine, apart from the dexamethasone 8 mg, had no pain immediately after surgery. These findings accord with those of others.33–36

Our study has important limitations that are to be avoided in future research. We performed the three studies in a consecutive order so that dexamethasone was not blindly administered (Figure 1). This may have influenced expectations and subsequently postoperative pain scores. A further limitation was the small number of patients in each group. Thus, negative results are to be interpreted with caution. Furthermore, we only measured cytokine levels measured at a single time point postoperatively. Hence, we cannot draw any firm conclusions whether the early postoperative immune imbalance could explain the acute pain and complications. Lastly, we used current literature3,9,20 to designate not only infections but also pain as complications with a potential immune-mediated mechanism. Notwithstanding, we conceivably missed other specific immune-mediated complications which could have influenced our results.

A strength is that we performed a single-center study with a small team and a strictly protocolized environment. Consequently, inclusion rate was rather low. An extra delaying factor was that we had to switch from a standard to a more sensitive measuring method to assess very low cytokine concentrations.18 Thus, time bias cannot be ruled out.

### Table 3 Relationships Between Cytokine Levels, Pain Scores and Postoperative Complications

<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds Ratio (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t2</td>
<td>1.464 (0.941–2.278)</td>
<td>0.091</td>
</tr>
<tr>
<td>t2</td>
<td>2.028 (1.134–3.628)</td>
<td>0.017</td>
</tr>
<tr>
<td>IL-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t0</td>
<td>1.359 (0.918–2.010)</td>
<td>0.125</td>
</tr>
<tr>
<td>t2</td>
<td>1.036 (0.992–1.082)</td>
<td>0.113</td>
</tr>
<tr>
<td>IL-10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t0</td>
<td>0.690 (0.207–2.301)</td>
<td>0.546</td>
</tr>
<tr>
<td>t2</td>
<td>1.053 (0.963–1.151)</td>
<td>0.255</td>
</tr>
<tr>
<td>IL-6/IL-10</td>
<td>(0.848–10.047)</td>
<td>0.089</td>
</tr>
<tr>
<td>IL-1β</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t0</td>
<td>0.321 (0.007–14.874)</td>
<td>0.561</td>
</tr>
<tr>
<td>t2</td>
<td>0.802 (0.228–2.822)</td>
<td>0.731</td>
</tr>
<tr>
<td>IL-1Ra</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t0</td>
<td>1.003 (0.999–1.007)</td>
<td>0.136</td>
</tr>
<tr>
<td>t2</td>
<td>1.000 (0.999–1.001)</td>
<td>0.940</td>
</tr>
<tr>
<td>IL-1β/IL-1Ra*</td>
<td>(0.167–1.623)</td>
<td>0.261</td>
</tr>
<tr>
<td>t2</td>
<td>1.251 (0.601–2.605)</td>
<td>0.549</td>
</tr>
</tbody>
</table>

Notes: Odds ratios with 95% confidence intervals (CI) obtained from univariate binary logistic regressions estimating the association between pain scores or cytokine levels on one hand and the occurrence of a 30-day complication on the other. For pain scores, which were obtained with Numeric Rating Scale (NRS) at 4 hours after operation (t2) the dependent variable was the occurrence of any complication according to the CDC or only a potentially immune-related complication (PIRC). For cytokine levels and two of their ratios at baseline (t0) and t2, the dependent variable was the occurrence of a PIRC. NRS was associated with PIRC in these univariate analyses. Results for IL-1β/IL-1Ra are to be multiplied by 10^9.
Conclusions
Our study suggests research subjects for future larger scale studies in patients undergoing a lumpectomy for breast cancer. (1) Confirming that dexamethasone 4 mg or 8 mg, but not IV lidocaine, modulates the cytokine response into an anti-inflammatory direction. These effects should be evaluated by measuring cytokine levels on several time points postoperatively and surgery duration should be included as a variable. (2) Investigating the relation between acute pain and postoperative complications, especially PIRC’s. (3) Investigating the relation between 30-day complications and the preoperative ratio IL-6/IL-10 or other immune-mediated mechanisms.

Perioperatively a dynamic balance exists between pro- and anti-inflammatory cytokins. It is still an ongoing debate about the kind of immune balance we should aim at. Although larger studies are needed, we provided new pieces of information that may help developing a multimodal approach to the prevention of complications after breast cancer surgery.

Abbreviations
CDC, Clavien Dindo Classification; CI, confidence interval; IL, interleukin; IV, intravenous; NRS, Numeric Rating Scale; OR, odds ratio; PACU, post anesthesia care unit; PIRC, potential immune-related complications; SD, standard deviation.

Data Sharing Statement
The datasets generated during the current study are available from the corresponding author on reasonable request.

Disclosure
The authors report no conflicts of interest in this work.

References


Journal of Pain Research

**Publish your work in this journal**

The Journal of Pain Research is an international, peer reviewed, open access journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.